Dual peroxisome proliferator-activated receptor delta/gamma (PPARd/g) agonist with primary PPARd selectivity and brain-penetrant insulin-sensitizing activity
A non-thiazolidinedione dual nuclear receptor agonist originally developed for metabolic disease and repositioned as a first-in-class brain insulin-sensitizing therapy for Alzheimer’s disease, distinguished by concurrent PPARd and PPARg activation, high central nervous system penetrance, and Phase 2 evidence of disease-modifying effects on cognition and amyloid biomarkers.
Abstract
T3D-959 (DB-959, DB-959Na as the sodium salt) is an orally bioavailable, brain-penetrant, non-thiazolidinedione dual agonist of peroxisome proliferator-activated receptor delta (PPARd; human ED50 19 nM) and peroxisome proliferator-activated receptor gamma (PPARg; human ED50 297 nM), conferring approximately 15-fold selectivity for the delta isoform. The compound was originally synthesized by Bayer and advanced through Phase 1 clinical trials for dyslipidemia and type 2 diabetes by DARA BioSciences before being acquired in 2013 by T3D Therapeutics and repositioned as a disease-modifying candidate for Alzheimer’s disease (AD) on the basis of the “type 3 diabetes” hypothesis, which posits that sporadic AD is driven by progressive brain insulin resistance, deficient insulin and insulin-like growth factor signaling, and consequent neurometabolic dysfunction. T3D-959 is the first PPARd-activating compound to enter clinical development for AD and represents a mechanistically distinct approach from the anti-amyloid antibody and cholinesterase inhibitor classes that dominate the current AD therapeutic landscape. Preclinical characterization in the intracerebral streptozotocin (i.c. Therapeutic effects were observed even when treatment was delayed seven days after the STZ insult, suggesting relevance to mild and moderate disease stages. A separate preclinical study demonstrated that T3D-959 at 1.0 mg/kg/day improved motor function and prevented cerebellar white matter atrophy in the same model. Pharmacokinetic analysis confirmed dose-dependent systemic exposure exceeding the PPARd ED50 at all doses tested. Plasma metabolomics showed dose-dependent reductions in branched-chain amino acids and ceramides and increases in acylcarnitines, consistent with improved insulin sensitivity and enhanced fatty acid beta-oxidation. FDG-PET neuroimaging demonstrated dose-dependent increases in regional cerebral glucose metabolism, with the strongest effects in the putamen, anterior cingulate, insula, and orbital frontal cortex. The Phase 2 PIONEER trial, a 24-week multicenter randomized double-blind placebo-controlled study in 250 patients with mild to moderate AD, reported positive top-line results in November 2023 at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference. In the modified intent-to-treat population (n=141), the 30 mg group showed improvement on ADAS-Cog11 (0.73 versus 2.70 on placebo; p=0.073), and the 15 mg group showed improvement on ADCS-CGIC (0.39 versus 0.86 on placebo; p=0.060). Plasma amyloid beta 42/40 ratio improved significantly in the 30 mg (p=0.011) and 45 mg (p=0.033) groups, and the neurodegeneration marker neurogranin improved significantly in the 30 mg group (p=0.035). The compound was well tolerated, with adverse event rates similar between active and placebo arms (37.3% versus 43.1%) and no treatment-related serious adverse events. T3D-959 is not approved for any indication in any jurisdiction. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.